The year 2018 was when cannabidiol (CBD) "jumped the shark," according to a nurse practitioner who works with patients who use it.
“Who here has treated patients who are using CBD?” asked Andrew Penn, MS, NP, PMHNP-BC, an associate clinical professor at the University of California, San Francisco, School of Nursing.
Penn surveyed the ballroom as most of the hands shot up during a meeting of mental health professionals. “Yeah, I figured that’s why you’re here,” he said, opening up his presentation called “Confused About Cannabidiol (CBD)? A Scientific and Rational Examination of Its Risks and Benefits in Psychiatry.”
This year was the tipping point for CBD, he said; he realized that CBD had “jumped the shark” when a major brick-and-mortar retailer advertises “CBD for health and wellness“ in its promotional flyer as if they were scented candles or bed and bath products.
"Is CBD snake oil? I want to unpack that today,” he said.
The difference between tetrahydrocannabinol (THC) and CBD is that THC, with its profile of stunting intellectual development, dependence risk, and psychotomimetic and anxiogenic effects, often gets hit with a reputation as the “bad guy”; CBD, believed to counter THC and to be nonpsychoactive, gets the “good guy” label.
It’s not that simple, said Penn. “That kind of dichotomous thinking gets us into trouble,” he said.
CBD is not intoxicating, but it is psychoactive, he said, with multiple mechanisms of action that may be useful for various psychiatric conditions. However, the problem is that there have not been large clinical trials due to federal law classifying CBD and THC as Schedule 1 substances.
If CBD is a Schedule 1 substance, how is it being advertised? In 2018, the Farm Bill allowed for CBD that comes from hemp to be legal, under certain conditions, because the law removed hemp that contains less than 0.3% THC dry weight from the Controlled Substances Act. All other CBD, made in any other setting, remains a Schedule I substance and remains illegal under federal law.
The FDA is not doing a good job of enforcing health claims, he said. However, cannabis-derived CBD oil is legal in the 33 states that have some degree of regulation when it comes to medicinal or recreational use.
The doses of CBD that have been studied in the few clinical trials that have happened did show some benefit in studies of social anxiety and as an adjunct to treatment with antipsychotics and for the treatment of schizophrenia. However, the doses of CBD that were used in those trials far exceeded the amount that a person would take if self-treating, and would also be very expensive, he said. Patients are using doses of CBD that are much smaller than the doses that have been studied.
More information may come as more people use Epidiolex, the prescription CBD product the FDA approved in 2018 for patients with 2 rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. It is approved for patients 2 years of age and older. In addition, now that it is on the market, he said it is possible that it could be used by some doctors off-label, which will generate some information about how people are using it.
However, he said, patients should be told that we have limited data, and that gap of knowledge "is our fault," he said. Clinicians will need to learn from the stories of their patients.
"Until those studies are done, our patients are going to keep doing this, probably."
Becuase of the Schedule I classification, a researcher could only get funding to study CBD (or THC) was if they wanted to study its abuse potential. In addition, all researchers are required to obtain the plants from a federal farm at the University of Mississippi, where the quality of the plants are said to be low and not reppresentative of what people use in the real world.
"We are in a weird pre-post marketing world," said Penn.
In addition, he said, it is unknown what the effct is of using CBD over a long period of time. His reference would be to see it removed from Schedule I so it can be better studied.
"We’re really in this in between place where we’re not sure where this is going," he said.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More